首页>投融资
ANI Pharmaceuticals
增发
ANI Pharmaceuticals, Inc.于2001年4月成立于特拉华州。该公司是一家综合性的特种制药公司,致力于通过开发,制造和销售高质量的品牌和通用处方药来为公司的客户提供价值。 该公司专注于利基和高入口机会,包括受控物质,抗癌(溶瘤药),激素和类固醇,以及复杂的制剂。 该公司位于明尼苏达州Baudette的两家制药厂能够生产口服固体剂量产品,以及液体和局部,受控物质和必须在完全封闭的环境中制造的有效产品。 该公司的战略是使用其资产开发,收购,制造和销售品牌和通用专业处方药。
基本信息
-
公司全称ANI Pharmaceuticals Inc
-
类型药品制造商
-
产业领域药品研发/制造、生物药
-
公司人数500人以上
-
地址210 Main Street West Baudette Minnesota
-
联系电话1-218-6343500
-
邮箱pdonenberg@biosantepharma.com
-
成立时间1996-08-29
投融资
-
2023-05-16增发8625万美元未透露
-
2021-11-03增发7500万美元未透露
-
2017-12-19上市后再融资1.25亿美元Citizens Bank
-
2007-11-05上市未透露未透露
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem